1 week Ago By ABMN Staff
Orion Portfolio Solutions LLC lowered its stake in Genmab A/S ( NASDAQ:GMAB – Free Report ) by 18.4% in the 4th quarter, HoldingsChannel.com reports.
The firm owned 17,376 shares of the company’s stock after selling 3,919 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Genmab A/S were worth $363,000 at the end of the most recent reporting period. A number of other institutional investors also recently made changes to their positions in the stock.
EverSource Wealth Advisors LLC lifted its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after acquiring an additional 939 shares during the last quarter.
Lindbrook Capital LLC boosted its stake in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after buying an additional 950 shares during the period.
GAMMA Investing LLC grew its stake in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter.
Cromwell Holdings LLC grew its stake in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after buying an additional 2,496 shares in the last quarter.
Finally, R Squared Ltd bought a new stake in Genmab A/S in the fourth quarter worth approximately $93,000. 7.07% of the stock is owned by institutional investors and hedge funds.
Genmab A/S Price Performance Shares of Genmab A/S stock opened at $17.98 on Wednesday. The firm has a 50 day simple moving average of $20.
55 and a 200 day simple moving average of $21.44. The firm has a market cap of $11.
90 billion, a P/E ratio of 10.33, a P/E/G ratio of 2.65 and a beta of 1.
07. Genmab A/S has a fifty-two week low of $17.77 and a fifty-two week high of $30.
41. Analyst Upgrades and Downgrades Several analysts have recently issued reports on the company. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.
00 price target for the company in a research note on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd.
William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, Truist Financial lowered their price target on Genmab A/S from $50.
00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company.
According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.33. Read Our Latest Stock Analysis on GMAB Genmab A/S Profile ( Free Report ) Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. See Also Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S ( NASDAQ:GMAB – Free Report ).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter ..
